In Q1 2026, the Russian retail veterinary drug market saw synchronous growth in both physical and monetary volumes. Since the beginning of the year, Russians have purchased 71 million minimum dosage units (MDU) of animal drugs, which is 15% higher than in the same period of 2025. Consumer spending increased by 15.6%, exceeding RUB 13 billion (at retail prices, including VAT). The main driver of growth for the industry was March: over the month, more than 29 million MDU worth over RUB 6.8 billion were sold, with long-term growth compared to March 2025 recorded at +26.3% in rubles and +21.2% in MDU.

The online channel is demonstrating steady growth in the retail veterinary drug market. While in Q1 2025 its share of the total value of veterinary retail did not exceed 30%, in the first three months of this year it grew to 33.5%. In physical terms, the share increased from 21.9% to 29.4%. It is worth recalling that the historical peak of e-commerce development occurred in 2023, when sales doubled and the share jumped from 8.9% to 16.7%. Moreover, during periods of high seasonal demand, the online channel breaks even these records — in March of this year, its share exceeded 37%.

According to the "Retail Audit of Veterinary Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, Moscow, Moscow Oblast, and Krasnodar Krai lead the regional structure of the retail veterinary drug market – these three account for over 31% of all national spending, with the Russian capital providing about half of this amount (15% in rubles). In the first quarter of 2026, most federal subjects of the Russian Federation showed high growth in spending on veterinary drugs. The absolute leader in growth dynamics was the Republic of Kalmykia, where sales in rubles and MDU jumped threefold over the year. Among the top ten regions, the highest revenue growth was shown by Stavropol Krai (+24.5%) and Rostov Oblast (+23.3%). Only two regions in the top ten showed negative dynamics: Nizhny Novgorod and Novosibirsk Oblasts, where spending decreased by 5.3% and 6.1%, respectively. At the same time, Nizhny Novgorod Oblast also recorded the sharpest drop in physical consumption – down 37.7%.

Maximum consumer spending in all top regions during the reporting period was primarily directed toward the ectoparasitic drug Simparica from Zoetis and the dog vaccine Multikan (Vetbiokhim). In some regions of the country, such as Moscow Oblast, the second most popular brand is Tixfli (Vetpharmstandart), also used for protection against external parasites, which benefits from high advertising support. However, in the overall retail value volume, Simparica remains the undisputed leader, accounting for more than 10% of the market in value terms. Second place is held by Bravecto with a 5.4% share, while third place is occupied by Tixfli, which holds a 4.9% market share in rubles. At the same time, Tixfli surpasses Bravecto in physical units. Over the three months of this year, physical sales volume of Tixfli reached 290.7 thousand MDU, while sales of Bravecto amounted to 254.4 thousand units.